Safety and Efficacy of Overlapping Homogenous Drug-Eluting Stents in Patients with Acute Myocardial Infarction: Results from Korea Acute Myocardial Infarction Registry.
10.3346/jkms.2012.27.11.1339
- Author:
Khurshid AHMED
1
;
Myung Ho JEONG
;
Rabin CHAKRABORTY
;
Young Joon HONG
;
Doo Sun SIM
;
Sumera AHMED
;
Seung Hwan HWANG
;
Min Goo LEE
;
Keun Ho PARK
;
Ju Han KIM
;
Youngkeun AHN
;
Myeong Chan CHO
;
Chong Jin KIM
;
Young Jo KIM
;
Jong Chun PARK
;
Jung Chaee KANG
Author Information
1. The Heart Center of Chonnam National University Hospital, Chonnam National University Research Institute of Medical Sciences, Gwangju, Korea. myungho@chollian.net
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords:
Drug-Eluting Stents;
Myocardial Infarction;
Coronary Angioplasty
- MeSH:
Acute Disease;
Aged;
Aged, 80 and over;
Antineoplastic Agents, Phytogenic/adverse effects/*therapeutic use;
Coronary Angiography;
Drug-Eluting Stents/*adverse effects;
Female;
Humans;
Immunosuppressive Agents/adverse effects/*therapeutic use;
Male;
Middle Aged;
Myocardial Infarction/*drug therapy/mortality/pathology;
Myocardial Revascularization;
Paclitaxel/adverse effects/therapeutic use;
Proportional Hazards Models;
Registries;
Republic of Korea;
Sirolimus/adverse effects/analogs & derivatives/therapeutic use;
Survival Analysis
- From:Journal of Korean Medical Science
2012;27(11):1339-1346
- CountryRepublic of Korea
- Language:English
-
Abstract:
The aim of this study was to compare safety and efficacy of 4 homogenous overlapping drug-eluting stents (DES) in acute myocardial infarction (AMI) patients. We selected 1,349 consecutive patients (62.1 +/- 14.9 yr, 69.4% male) who received homogenous overlapping DESs in diffuse de novo coronary lesions from Korea Acute Myocardial Infarction Registry from April 2006 through September 2010. They were divided into 4 groups based on type of DES implanted - Paclitaxel (PES), Sirolimus (SES), Zotarolimus (ZES) and Everolimus (EES)-eluting stents. Primary endpoint was 12-month MACE. We also studied EES versus other DESs (PES + SES + ZES). Mean stent length was 26.2 +/- 7.5 mm and mean stent diameter was 3.1 +/- 0.4 mm. Average number of stents used per vessel was 2.2 +/- 0.5. Incidence of major adverse cardiac events (MACE) in PES, SES, ZES, and EES groups were 9.5%, 9.2%, 7.5%, and 3.8%, respectively (P = 0.013). In EES group, overall MACE and repeat revascularization were lowest, and no incidence of stent thrombosis was observed. Non-fatal MI was highest in PES, almost similar in SES and EES with no incidence in ZES group (P = 0.044). Cox proportional hazard analysis revealed no differences in the incidence of primary endpoint (P = 0.409). This study shows no significant differences in 12-month MACE among 4 groups.
